EUVIMEDEUVIMED entdecken
Crossref

Long‐term and low‐dose rituximab treatment for chronic inflammatory demyelinating polyneuropathy

Yongsheng Zheng iD, Chong Sun, Yanyin Zhao, Quanhua Meng, Jianian Hu, Kai Qiao, Jian Sun, Jianying Xi, Sushan Luo, Jiahong Lu, Chongbo Zhao, Jie Lin

Journal of the Peripheral Nervous System · 2024

DOI: 10.1111/jns.12653 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Peripheral Nervous System, 2024. Verfasst von Yongsheng Zheng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Huashan Hospital Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Rituximab, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Immunologic Factors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the efficacy and safety of a low‐dose, long‐term rituximab regimen in the treatment of idiopathic CIDP.

Methods

This study included 15 CIDP patients treated with rituximab. Patients were administered 600 mg of rituximab intravenously every 6 months. Baseline evaluation was conducted before the initiation of rituximab treatment and subsequent evaluations were conducted 6 months after each rituximab infusion at on‐site visits. Clinical improvement was objectively determined by improvement of scale score at least decrease ≥1 INCAT or mRS or increase ≥4 MRC or ≥8 cI‐RODS after each infusion compared to baseline evaluation.

Results

Fifteen CIDP patients were included and 10 of them were typical CIDP and five were distal CIDP. Nine in 15 (60%) patients after first infusion and three in six (50%) patients after second infusion exhibited significant clinical improvement compared to baseline evaluation. Additionally, rituximab facilitated a reduction or cessation of other medications in 73% of patients at last visit. The safety profile was favorable, with no reported adverse events.

Conclusion

Rituximab presents a promising therapeutic option for idiopathic CIDP, offering both efficacy and safety with a low‐dose, long‐term regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabPolyradiculoneuropathy, Chronic Inflammatory DemyelinatingImmunologic FactorsHumansMaleMiddle AgedFemaleAgedAdultTreatment Outcome

Stichwörter der Autor:innen

chronic inflammatory demyelinating polyneuropathylong termlow‐doserituximabtreatment

Substanzen

RituximabImmunologic Factors

Autor:innen und Institutionen

  • Department of Neurology, Huashan Hospital Fudan University, Shanghai, China.
  • National Center for Neurological Disorders (NCND), Shanghai, China.
  • Huashan Rare Disease Center, Huashan Hospital Fudan University, Shanghai, China.
  • Department of Neurology, Deyang People's Hospital, Deyang, China.

ORCID-Profile: Yongsheng Zheng

Zitieren

APA

Zheng, Y., Sun, C., Zhao, Y., Meng, Q., Hu, J., Qiao, K., Sun, J., Xi, J., Luo, S., Lu, J., Zhao, C., & Lin, J. (2024). Long‐term and low‐dose rituximab treatment for chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System. https://doi.org/10.1111/jns.12653

Vancouver

Zheng Y, Sun C, Zhao Y, Meng Q, Hu J, Qiao K, et al. Long‐term and low‐dose rituximab treatment for chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System. 2024. doi:10.1111/jns.12653

BibTeX
@article{Zheng2024,
  author = {Zheng, Yongsheng and Sun, Chong and Zhao, Yanyin and Meng, Quanhua and Hu, Jianian and Qiao, Kai and Sun, Jian and Xi, Jianying and Luo, Sushan and Lu, Jiahong and Zhao, Chongbo and Lin, Jie},
  title = {Long‐term and low‐dose rituximab treatment for chronic inflammatory demyelinating polyneuropathy},
  journal = {Journal of the Peripheral Nervous System},
  year = {2024},
  doi = {10.1111/jns.12653}
}
Kostenlos starten →